New Blood Test Reveals Hidden Mesothelioma Even Scans Miss

Blood Test Spots Hidden Mesothelioma that Scans Can't See A groundbreaking study has revealed a new blood test capable of detecting mesothelioma, a rare and aggressive cancer, even when scans fail to identify it. The innovative test uses circulating tumor DNA (ctDNA) to detect the presence of the disease in patients with diffuse pleural mesothelioma. According to researchers at Georgetown University Medical Center, the phase II clinical trial demonstrated that immunotherapy given before and after surgery significantly improved outcomes for patients with operable mesothelioma. The study's lead author, Dr. Lee M. Krug, stated, "This is a major breakthrough in our understanding of mesothelioma and its treatment. Our results show that a combination of immunotherapy and surgery can be highly effective in treating this aggressive cancer." Mesothelioma is a rare cancer that affects the tissue lining many organs, including the lungs, abdomen, and heart. Approximately 30,000 cases are diagnosed worldwide each year, with most occurring in the pleura, or lining surrounding the lungs. The new blood test, which uses ctDNA to detect genetic mutations associated with mesothelioma, has been hailed as a game-changer for patients and doctors alike. "This test is a significant advancement in our ability to diagnose mesothelioma," said Dr. Krug. "It allows us to identify patients who may benefit from immunotherapy and surgery, even if scans are inconclusive." Background research suggests that mesothelioma is often misdiagnosed or underdiagnosed due to its similarity in symptoms to other conditions. The new blood test aims to address this issue by providing a more accurate diagnosis. While the study's results are promising, experts emphasize that further research is needed to confirm these findings and explore their applicability to patients with non-resectable mesothelioma. Dr. Krug noted, "We're excited about the potential of this treatment approach, but we need to continue studying it to ensure its effectiveness in a broader range of patients." The study's results were presented at the World Conference on Lung Cancer and have sparked renewed interest in immunotherapy as a treatment option for mesothelioma. As researchers continue to investigate the benefits of this approach, patients and families affected by mesothelioma can take heart from these promising developments. Current Status: The study's results are based on a phase II clinical trial involving 30 patients with operable diffuse pleural mesothelioma. Immunotherapy was given before and after surgery in combination with standard treatment protocols. Patients who received immunotherapy showed significant improvements in outcomes, including longer survival rates. Next Developments: Researchers plan to conduct further studies to confirm the effectiveness of this approach in a larger patient population. The new blood test is being developed for commercial use, pending regulatory approval. Experts recommend that patients with suspected mesothelioma consult their healthcare providers about the potential benefits and risks of immunotherapy. *Reporting by Sciencedaily.*